According to a recent article in Business Week, General Electric is facing a growing number of concerns about Omniscan. The gadolinium-based drug is used in MRI scans and may be linked to nephrogenic systemic fibrosis (NSF). 

Omniscan is one of a number of similar products that is being tied to kidney disease in some patients. According to the article, GE has 30% of the drug market, while Bayer HealthCare has 50% of the market. 

If some of the cases against GE force the company to compensate victims for their injuries related to Omniscan, then the verdicts could hurt the company's growing health-care division. 

If you or anyone you know has sustained injuries after undergoing an MRI scan with a gadolinium-based agent, contact the gadolinium lawyers of Williams Kherkher at 800-761-3187.